Subscribe
shutterstock_1589330521_viktoria_kurpas
Viktoria Kurpas / Shutterstock.com
14 September 2020BiotechnologyMuireann Bolger

LSPN Connect: Invention harvesting

In the fast-paced environment of life sciences, the need for the IP sector to take full advantage of potential and emerging innovations is paramount, as a LSPN Connect session discovered.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
LSPN 19: AI ‘explosion’ and drug costs in Canada
17 October 2019   Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.
Americas
LSPN 19: Courts need to revisit patentability of diagnostic tests
26 April 2019   US courts need to revisit the patentability of diagnostic tests under section 101, according to Memorial Sloan Kettering Cancer Center’s chief IP counsel.


Editor's picks

Explainer: ARIPO’s role in Plant Variety Protection
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025

Editor's picks

Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025

More on this story

Big Pharma
LSPN 19: AI ‘explosion’ and drug costs in Canada
17 October 2019   Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.
Americas
LSPN 19: Courts need to revisit patentability of diagnostic tests
26 April 2019   US courts need to revisit the patentability of diagnostic tests under section 101, according to Memorial Sloan Kettering Cancer Center’s chief IP counsel.

More on this story

Big Pharma
LSPN 19: AI ‘explosion’ and drug costs in Canada
17 October 2019   Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.
Americas
LSPN 19: Courts need to revisit patentability of diagnostic tests
26 April 2019   US courts need to revisit the patentability of diagnostic tests under section 101, according to Memorial Sloan Kettering Cancer Center’s chief IP counsel.

More features

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Explainer: ARIPO’s role in Plant Variety Protection
J&J sues over schizophrenia drug generic following patent victory
WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era
Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids